Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1649 1675
This examiner grants 38% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 16088031 | BIOMARKERS OF PROTEOPATHIES AND USES THEREOF | Final Rejection | Genzyme Corporation |
| 17992403 | Agents, Uses and Methods for the Treatment of Synucleinopathy | Final Rejection | H. Lundbeck A/S |
| 18066469 | CHIMERIC ANTIBODIES FOR TREATMENT OF AMYLOID DEPOSITION DISEASES | Final Rejection | The Trustees of Columbia University in the City of New York |
| 17640627 | COMPOSITIONS AND METHODS FOR USING SILK-ELASTINLIKE PROTEIN-BASED POLYMERS | Non-Final OA | University of Utah Research Foundation |
| 18004479 | Biomarkers for Identifying Relapses in Multiple Sclerosis | Non-Final OA | The Board of Regents of the University of Oklahoma |
| 18054457 | ANTIBODIES FOR THE TREATMENT OF SYNUCLEINOPATHIES AND NEUROINFLAMMATION | Non-Final OA | MOR RESEARCH APPLICATIONS LTD. |
| 17914817 | Uses of Tau Phosphosites as Biomarkers for Alzheimer's Disease | Non-Final OA | Washington University |
| 17742050 | Activity Modulator | Non-Final OA | University of Tsukuba |
| 17820815 | DIAGNOSTIC BIOMARKERS FOR DETECTING, SUBTYPING, AND/OR ASSESSING PROGRESSION OF MULTIPLE SCLEROSIS | Non-Final OA | Rowan University |
| 18360222 | Modified anti-PD-L1 Antibody and Methods and Uses for Treating a Neurodegenerative Disease | Non-Final OA | Yeda Research and Development Co. Ltd. |
| 17051857 | DETECTION OF AUTOANTIBODIES AGAINST DEIMINATED PROTEIN EPITOPES ASSOCIATED WITH BRAIN OXYGEN DEPRIVATION | Final Rejection | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. |
| 18426786 | DETECTION OF MISFOLDED ALPHA SYNUCLEIN PROTEIN | Non-Final OA | Amprion, Inc. |
| 18178055 | PERSONALIZED IMMUNOTHERAPY AGAINST SEVERAL NEURONAL AND BRAIN TUMORS | Non-Final OA | Immatics Biotechnologies GmbH |
| 18354403 | PSILOCYBIN COMPOSITIONS | Non-Final OA | TURTLE BEAR HOLDINGS, LLC |
| 18114381 | PSILOCYBIN COMPOSITIONS | Non-Final OA | TURTLE BEAR HOLDINGS, LLC |
| 18271804 | ANTIGEN-BINDING PROTEIN TARGETING STAPHYLOCOCCUS AUREUS a-HEMOLYSIS AND APPLICATION THEREOF | Non-Final OA | Starmob Biologics (Shanghai) Co., Ltd. |
| 17818481 | NEW TAU SPECIES | Final Rejection | ECOLE SUPERIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS |
| 18333797 | HUMAN NEUREGULIN-1 (NRG-1) RECOMBINANT FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | Salubris (Chengdu) Biotech Co., Ltd. |
| 18265617 | OPTIC NERVE PROTECTING AGENT CONTAINING ANTI-LRP1 ANTIBODY | Non-Final OA | NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION |
| 18324955 | METHODS FOR DETECTING EARLY DAMAGE OF BLOOD-BRAIN BARRIER DURING CEREBRAL ISCHEMIC STROKE AND APPLICATION THEREOF | Non-Final OA | XUANWU HOSPITAL OF CAPITAL MEDICAL UNIVERSITY |
| 18324952 | METHODS FOR DETECTING EARLY DAMAGE OF BLOOD-BRAIN BARRIER IN ISCHEMIC STROKE AND APPLICATION THEREOF | Non-Final OA | XUANWU HOSPITAL OF CAPITAL MEDICAL UNIVERSITY |
| 18188707 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING INFLAMMATION | Non-Final OA | RSEM, LIMITED PARTNERSHIP |
| 17783143 | Compounds for treatment of eye diseases | Final Rejection | Region Midtjylland |
| 18155230 | METHODS AND COMPOSITIONS FOR THE GENERATION AND USE OF HUMANIZED CONFORMATION-SPECIFIC PHOSPHORYLATED TAU ANTIBODIES | Final Rejection | Pinteon Therapeutics Inc. |
| 18004287 | METHOD FOR PRODUCING A MAMMALIAN BRAIN PROTEIN HYDROLYSATE | Non-Final OA | EVER Neuro Pharma GmbH |
| 14346822 | STIMULUS-ELICITED GENOMIC PROFILE MARKERS OF A NEURODEGENERATIVE CONDITION | Non-Final OA | West Virginia University |
| 17257055 | COMPOSITIONS AND METHODS FOR REDUCTION OF LIPOPROTEIN A FORMATION AND TREATMENT OF AORTIC VALVE SCLEROSIS AND AORTIC STENOSIS | Final Rejection | Abcentra, LLC |
| 16971288 | USE OF IL-34 TO TREAT RETINAL INFLAMMATION AND NEURODEGENERATION | Non-Final OA | THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Se |
| 16099188 | SYNAPTIC PROTEIN BIOMARKERS AND DIFFERENTIAL DIAGNOSIS OF ALZHEIMER'S DISEASE AND OTHER NEURODEGENERATIVE DISORDERS | Non-Final OA | NANOSOMIX, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy